Rectal Cancer Watch & Wait Management: Experience of 545 Patients from the U.S. Rectal Cancer Research Group.

IF 3.2 2区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Diseases of the Colon & Rectum Pub Date : 2024-11-07 DOI:10.1097/DCR.0000000000003586
Samuel H Lai, Maria Widmar, John R T Monson, Fergal J Fleming, Arden M Morris, Jon D Vogel
{"title":"Rectal Cancer Watch & Wait Management: Experience of 545 Patients from the U.S. Rectal Cancer Research Group.","authors":"Samuel H Lai, Maria Widmar, John R T Monson, Fergal J Fleming, Arden M Morris, Jon D Vogel","doi":"10.1097/DCR.0000000000003586","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of a watch and wait management strategy following a complete clinical response to neoadjuvant therapy for rectal cancer is increasing. However, insights into implementation, treatments, and outcomes, on a United States national level, are limited.</p><p><strong>Objective: </strong>To investigate and report on watch & wait management practices and outcomes in the US.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Setting: </strong>Multicenter.</p><p><strong>Patients: </strong>Stage II or III rectal cancer patients who underwent intentional watch & wait management between January 2015 and August 2022.</p><p><strong>Main outcome measures: </strong>Patient and tumor characteristics, neoadjuvant treatment and response, local cancer regrowth and metastasis, salvage surgery, overall and disease-specific survival.</p><p><strong>Results: </strong>Among 545 patients from 33 centers, follow-up was 21 months (range, 9-37). Total neoadjuvant therapy or other types of neoadjuvant were used in 395 (72%) and 150 (28%) of patients, respectively. Estimated 3-year local regrowth rate was 23.8% (95% CI: 19.1-29.4%). Patients with local regrowth had higher distant metastases incidence (14.2% vs. 3.5%, p < 0.001). Salvage surgery was performed in 74/84 (88%) patients with local regrowth and included rectal resection in 66 (89%), and local excision in 8 (11%). Of 64 salvage resections with known pathology results, 58 (91%) were margin-negative. Overall, 3-year overall survival was 94.8% (95% CI: 90.5 - 97.2%) and 3-year disease specific survival 96.2% (95% Cl 91.8 - 98.2%). Patients with and without local regrowth exhibited 3-year overall survival of 83.6% (95% Cl 68.4 - 91.9%), and 97.7% (95% CI: 93.3 - 99.2%), respectively.</p><p><strong>Limitations: </strong>Retrospective study.</p><p><strong>Conclusion: </strong>This multicenter study indicates that the watch & wait approach for locally advanced rectal cancer is feasible with acceptable outcomes across a variety of geographical regions and practice settings in the US. Local regrowth and distant metastasis rates were within published norms and salvage surgery proved effective. See Video Abstract.</p>","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the Colon & Rectum","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DCR.0000000000003586","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The use of a watch and wait management strategy following a complete clinical response to neoadjuvant therapy for rectal cancer is increasing. However, insights into implementation, treatments, and outcomes, on a United States national level, are limited.

Objective: To investigate and report on watch & wait management practices and outcomes in the US.

Design: Retrospective study.

Setting: Multicenter.

Patients: Stage II or III rectal cancer patients who underwent intentional watch & wait management between January 2015 and August 2022.

Main outcome measures: Patient and tumor characteristics, neoadjuvant treatment and response, local cancer regrowth and metastasis, salvage surgery, overall and disease-specific survival.

Results: Among 545 patients from 33 centers, follow-up was 21 months (range, 9-37). Total neoadjuvant therapy or other types of neoadjuvant were used in 395 (72%) and 150 (28%) of patients, respectively. Estimated 3-year local regrowth rate was 23.8% (95% CI: 19.1-29.4%). Patients with local regrowth had higher distant metastases incidence (14.2% vs. 3.5%, p < 0.001). Salvage surgery was performed in 74/84 (88%) patients with local regrowth and included rectal resection in 66 (89%), and local excision in 8 (11%). Of 64 salvage resections with known pathology results, 58 (91%) were margin-negative. Overall, 3-year overall survival was 94.8% (95% CI: 90.5 - 97.2%) and 3-year disease specific survival 96.2% (95% Cl 91.8 - 98.2%). Patients with and without local regrowth exhibited 3-year overall survival of 83.6% (95% Cl 68.4 - 91.9%), and 97.7% (95% CI: 93.3 - 99.2%), respectively.

Limitations: Retrospective study.

Conclusion: This multicenter study indicates that the watch & wait approach for locally advanced rectal cancer is feasible with acceptable outcomes across a variety of geographical regions and practice settings in the US. Local regrowth and distant metastasis rates were within published norms and salvage surgery proved effective. See Video Abstract.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
直肠癌观察与等待管理:美国直肠癌研究小组 545 名患者的经验。
背景:直肠癌新辅助治疗完全临床应答后,观察和等待管理策略的使用越来越多。然而,在美国全国范围内,对该策略的实施、治疗和结果的了解还很有限:调查并报告美国的观察与等待管理实践和结果:设计:回顾性研究:患者:II期或III期直肠癌患者2015年1月至2022年8月期间接受有意观察和等待管理的II期或III期直肠癌患者:患者和肿瘤特征、新辅助治疗和反应、局部癌症再生和转移、挽救手术、总生存期和疾病特异性生存期:在来自33个中心的545名患者中,随访时间为21个月(9-37个月)。分别有395例(72%)和150例(28%)患者采用了新辅助治疗或其他类型的新辅助治疗。估计3年局部再生率为23.8%(95% CI:19.1-29.4%)。局部再生患者的远处转移发生率较高(14.2% 对 3.5%,P < 0.001)。74/84(88%)例局部再生患者接受了挽救手术,其中66例(89%)接受了直肠切除术,8例(11%)接受了局部切除术。在 64 例已知病理结果的挽救性切除术中,58 例(91%)为边缘阴性。总体而言,3 年总生存率为 94.8%(95% CI:90.5 - 97.2%),3 年疾病特异性生存率为 96.2%(95% Cl 91.8 - 98.2%)。有局部再生和无局部再生的患者3年总生存率分别为83.6%(95% Cl 68.4 - 91.9%)和97.7%(95% CI:93.3 - 99.2%):局限性:回顾性研究:这项多中心研究表明,对局部晚期直肠癌采取观察和等待的方法是可行的,其结果在美国不同的地理区域和实践环境中都是可以接受的。局部再生率和远处转移率均在公布的标准范围内,抢救性手术证明是有效的。参见视频摘要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.50
自引率
7.70%
发文量
572
审稿时长
3-8 weeks
期刊介绍: Diseases of the Colon & Rectum (DCR) is the official journal of the American Society of Colon and Rectal Surgeons (ASCRS) dedicated to advancing the knowledge of intestinal disorders by providing a forum for communication amongst their members. The journal features timely editorials, original contributions and technical notes.
期刊最新文献
Barriers to Colonoscopy Quality Measurement in Rural Wisconsin. Being Remembered. Garnet Ault: The First Canadian President of the American Proctologic Society. Novel Technique: Colonic Sleeve Resection in Endometriosis. Colonoscopy Assisted Laparoscopic Wedge Resection for Colonic Lesions: Impact on Quality of LifE: Results from the LIMERIC Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1